peopleInnovationCareers RarePipelineCollaborationFinanceAdvance treatment Skip to main contentSkip to navigationSkip to search
Hansa Biopharma
HNSA (, %) SEK
Hansa Biopharma

Hansa Biopharma to participate in two upcoming investor conferences

25 Feb 2020, 08:00
Hansa Biopharma has been invited to participate in two global biotech and healthcare conferences during March including Cowen Annual Health Care Conference in Boston and Carnegie Nordic Healthcare Seminar in Stockholm.

Lund, Sweden February 25, 2020. Hansa Biopharma, the leader in immunomodulatory enzyme technology for rare IgG mediated diseases, today announced that the Company’s management team will participate in the following upcoming investor conferences: 

•    Cowen and Company’s 40th Annual Health Care Conference in Boston on Monday, March 2, 2020, with a presentation at 4:10 PM EST/ 22:10 CET on the same day.
•    The Carnegie Nordic Healthcare Seminar in Stockholm on Wednesday, March 4, 2020, with a presentation at 8:00 AM CET

A live webcast of the Cowen presentation will be available on the Events & Webcast page of the Company's website, A replay of the presentation will be available approximately two hours after the event and will be available for two weeks following the presentation.

Calendar 2020

 Feb 27-28, 2020  Road Show Cowen, Chicago/Dallas 
 Mar 2, 2020  Cowen Annual Health Care Conference, Boston
 Mar 4, 2020  Road Show Argot, New York City
 Mar 4, 2020   Carnegie Nordic Healthcare Seminar, Stockholm
 Mar 26, 2020  Kempen Expert Call with Prof. Mårten Segelmark on Anti-GBM
 Apr 2, 2020  Annual Report 2019
 Apr 21-22, 2020  Kempen Life Sciences Conference, Amsterdam 
 Apr 28, 2020  Interim Report Jan-Mar 2020
 May 5, 2020  Annual General Meeting
 May 18, 2020  UBS Global Healthcare Conference, NYC
 May 19, 2020  RBC Global Healthcare Conference, NYC
 May 26, 2020  ABG Life Science Summit, Stockholm
 May 27, 2020  Ökonomisk Ugebrev Life Science Conference, Copenhagen
 Jul 16, 2020  Interimn Report Jan-Jul 2020
 Sep 16-17, 2020  Bank of America Merill Lynch Global Healthcare Conf., London
 Oct 22, 2020  Interimn Report Jan-Sep 2020

For further information, please contact:
Klaus Sindahl, Head of Investor Relations
Hansa Biopharma
Mobile: +46 (0) 709-298 269

Rolf Gulliksen, Head of Corporate Communications
Hansa Biopharma
Mobile: +46 (0) 733-328 634

About Hansa Biopharma
Hansa Biopharma is leveraging its proprietary immunomodulatory enzyme technology platform to develop treatments for rare immunoglobulin G (IgG)-mediated autoimmune conditions, transplant rejection and cancer. The Company’s lead product candidate, imlifidase, is a unique antibody-cleaving enzyme that potentially may enable kidney transplantation in highly sensitized patients with potential for further development in other solid organ transplantation and acute autoimmune indications. Imlifidase is currently under review for marketing authorization by EMA. Hansa’s research and development program is advancing the next generation of the Company’s technology to develop novel IgG-cleaving enzymes with lower immunogenicity, suitable for repeat dosing in relapsing autoimmune diseases and oncology. Hansa Biopharma is based in Lund, Sweden and also has operations in Europe and US.